ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

With new long-term survival data at the recently concluded American Society of Clinical Oncology meeting, Johnson & Johnson and Legend Biotech are less and less shy about using the word “cure” in connection with their CAR-T cell therapy Carvykti (ciltacabtagene autoleucel) for multiple myeloma. But whether the therapy is truly curative will depend on how the International Myeloma Foundation’s International Myeloma Working Group (IMWG) defines the term.

Key Takeaways

Data from the CARTITUDE-1 trial showed one-third of patients achieving progression-free status for five years or more, including 12 with no trace of the disease.

J&J presented data from the Phase Ib/II CARTITUDE-1 study in an oral session at the ASCO meeting, which took place...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

13 Jun 2025

• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.